1 Department of Pediatrics, Children's Hospital and Regional Medical Center, Seattle 98105; and Departments of 2 Medicine, 3 Anesthesiology, and 4 Environmental Health, University of Washington, Seattle, Washington 98108
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We investigated the source(s) for exhaled nitric oxide (NO) in isolated, perfused rabbits lungs by using isozyme-specific nitric oxide synthase (NOS) inhibitors and antibodies. Each inhibitor was studied under normoxia and hypoxia. Only nitro-L-arginine methyl ester (L-NAME, a nonselective NOS inhibitor) reduced exhaled NO and increased hypoxic pulmonary vasoconstriction (HPV), in contrast to 1400W, an inhibitor of inducible NOS (iNOS), and 7-nitroindazole, an inhibitor of neuronal NOS (nNOS). Acetylcholine-mediated stimulation of vascular endothelial NOS (eNOS) increased exhaled NO and could only be inhibited by L-NAME. Selective inhibition of airway and alveolar epithelial NO production by nebulized L-NAME decreased exhaled NO and increased hypoxic pulmonary artery pressure. Immunohistochemistry demonstrated extensive staining for eNOS in the epithelia, vasculature, and lymphatic tissue. There was no staining for iNOS but moderate staining for nNOS in the ciliated cells of the epithelia, lymphoid tissue, and cartilage cells. Our findings show virtually all exhaled NO in the rabbit lung is produced by eNOS, which is present throughout the airways, alveoli, and vessels. Both vascular and epithelial-derived NO modulate HPV.
nitric oxide synthase inhibitors; isolated perfused lung; 1400W; 7-nitroindazole; nitro-L-arginine methyl ester
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
NITRIC OXIDE (NO) produced within the lungs plays an important role in the regulation of a number of physiological and pathophysiological processes. These include bronchial and vascular smooth muscle relaxation, neurotransmission, and host defense. NO is produced by three isozymes of nitric oxide synthase (NOS): neuronal (nNOS or NOS I), inducible (iNOS or NOS II), and endothelial (eNOS or NOS III). Their expression and location in the respiratory tract vary between species and with disease states (reviewed in Ref. 13).
In mammals, exhaled NO is produced both by the epithelium of the nose and sinuses (15, 20) and the lower respiratory tract, including airways, blood vessels, nerves, and alveolar epithelium (6, 7, 25, 27-29). The sources and origins of exhaled NO from the lower respiratory tract remain poorly defined, both the anatomical location of its production and the relative roles of each isozyme contributing to total NO synthesis. It has been claimed that the contribution of the vascular endothelium to exhaled NO is relatively minor in vivo as most of the produced NO is bound avidly and rapidly by hemoglobin in circulating red blood cells and surrounding vascular smooth muscle (27). However, we have demonstrated in certain situations that changes in vascular NO turnover can be reflected in exhaled NO (1).
The availability of selective NOS inhibitors and isozyme-specific antibodies make it possible to study the relative contributions of the different isozymes to exhaled NO excretion, their location within the lung, their role in vascular regulation, and possibly the anatomical location of NO production appearing in exhaled gas. Thus we explored these questions in the isolated perfused rabbit lung using a variety of NOS inhibitors delivered by the vascular and inhaled routes and by immunocytochemistry. Studies were performed under normoxic and also under hypoxic conditions to determine the effects of inhibiting NOS isozymes on hypoxic pulmonary vasoconstriction (HPV), a critical ventilation-perfusion-matching mechanism known to be modulated by NO (7).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Experimental preparation. The protocol was approved by the Animal Care Committee of the Veterans Administration Puget Sound Health Care System. Pathogen-free New Zealand White rabbits weighing 3.2 ± 0.2 kg, range 2.9-3.6 kg (West Oregon Rabbit Farm, Philomath, OR), were anesthetized with ketamine (10 mg/kg) and xylazine (0.33 mg/kg) injected through an ear vein. We performed a tracheotomy and ventilated the rabbit with a volume-controlled ventilator (Siemens Servo 900; Siemens) using a tidal volume of 10 ml/kg, a respiratory rate of 20 breaths per min, zero positive end-expiratory pressure (PEEP), and inspired gas consisting of 21% O2, 5% CO2, and 74% N2. Pancuronium (1 mg/kg) was administered at the onset of mechanical ventilation.
After a median sternotomy, the rabbits were anticoagulated with intravenous heparin at a dose of 300 U/kg. The right carotid artery was cannulated, and the rabbits were exsanguinated. The left atrium and main pulmonary artery were cannulated and perfused in an antegrade fashion with Krebs-Henseleit solution at a rate of 150 ml · kgPharmacological agents. N-[3-(aminomethyl)benzyl] acetamidine (1400W) was used to selectively inhibit iNOS (34), and 7-nitroindazole (7-NI) was used to selectively inhibit nNOS (22). Both agents are active in the rabbit (23, 35), and the concentrations selected were those at the high end of their isozyme selectivity. At present there is no selective inhibitor of eNOS, thus its contribution was assessed indirectly by the use of nitro-L-arginine methyl ester (L-NAME), a nonselective inhibitor of all isozymes (7, 17). The eNOS contribution was taken as the difference between the results with 1400W plus 7-NI and those with L-NAME. Acetylcholine (ACh) was infused in some preparations to increase NO production by the vascular endothelium (6, 14) to amplify the contribution of vascular NO to exhaled gas. Three groups were studied and are described below with their specific protocols.
Group A: effects of selective and nonselective NOS inhibition on exhaled NO excretion and PAP in normoxia and hypoxia. After stabilization of the preparation, 7-NI and 1400W were added to the perfusate in a random manner. 1400W was diluted in 1.0 ml of normal saline and administered to yield a concentration of 0.4 µM. 7-NI was first dissolved in a small amount of DMSO and administered to achieve a concentration of 10 µM. After the first two NOS inhibitors, L-NAME was then administered to yield perfusate concentrations of 10 and 100 µM diluted in 1.0 ml of normal saline. These concentrations were chosen from previously published work (22, 34) in which near-maximal selective NOS isozyme inhibition was achieved. Fifteen minutes after the administration of each drug, PAP, LAP, exhaled NO, and airway pressures were recorded, and a 5-min period of hypoxic ventilation was initiated (n = 11). A 5-min period was then allowed before any further intervention. Controls received vehicle in the form of saline or saline with DMSO (n = 5).
Group B: effects of ACh infusion and NOS inhibitors on exhaled NO
production and PAP in normoxia and hypoxia.
To determine the effects of infused ACh and stimulated vascular
endothelial NO production on exhaled NO excretion, we prepared the
rabbit model as described above, and measurements were taken after 30 min. After this stabilization period, ACh dissolved in saline was
infused at a dose of 1 µg · kg1 · min
1
(n = 5). Thereafter the protocol was identical to that
of group A. In the control group, normal saline or
saline plus DMSO was administered in place of all drugs
(n = 6).
Group C: effect of nebulized L-NAME on exhaled NO excretion and PAP in normoxia and hypoxia. To assess the airway and alveolar epithelial NOS contribution to exhaled NO and hypoxic vascular responses, we administered L-NAME by inhalation to concentrate its effect to nonvascular tissue. L-NAME in increasing doses (dissolved in 1 ml of normal saline) was nebulized over a 5-min period (n = 5). Doses were based on final concentrations in the perfusate if all the L-NAME was absorbed into the perfusate (100, 200, 500, 750, and 1,000 µM) with total doses of 7.4, 14.7, 36.9, 55.3, and 73.7 mg. A control group received nebulized saline in an identical manner (n = 4). At the end of each new incremental dose of L-NAME or saline, a 5-min hypoxic challenge was performed. In three experiments, L-NAME concentrations in the perfusate following each nebulization were measured by ion exchange high-pressure liquid chromatography (Waters, Milford, MA) with a lithium buffer using postcolumn ninhydrin derivatization (31) (Pickering, Mountain View, CA).
Immunohistochemistry. Rabbit lungs were fixed in phosphate-buffered 4% formalin. Blocks of tissue from the middle and lower lobes of both the right and left lungs were dehydrated and embedded in paraffin. Sections were cut at 8 µm. Most of the immunohistochemical steps were performed in a "moist chamber" (a 150-mm plastic petri dish with a wet pad of filter paper). All reactions were at room temperature with the one exception noted below.
The three isozymes of NOS were detected with mouse monoclonal antibodies (anti-nNOS, catalogue no. N31020; anti-iNOS, catalogue no. N32020; anti-eNOS, catalogue no. N30020) from Transduction Laboratories (Lexington, KY). Secondary antibodies and reagents for peroxidase and diaminobenzidine staining were in a kit from Dako ARK (Animal Research Kit, Peroxidase; Carpinteria, CA). We performed negative controls by excluding the primary antibody during the staining procedure. When it was obvious that we could not detect definite iNOS staining in the lung, we tested the antibody in a system known to express iNOS (a positive control) to assure its sensitivity and specificity. Murine macrophage cells (line J774A) were cultured in RPMI 1640 with 10% heat-inactivated fetal calf serum. For stimulation of iNOS, the cells were grown on glass coverslips in wells of 24-well plates until confluent. The medium was replace with fresh medium containing various concentrations of Escherichia coli LPS (100, 50, 25, 12.5, and 6.25 µg/ml). After 48 h, the cells were fixed and processed for iNOS immunohistochemistry. Antigen retrieval was done by flooding the sections with 1% SDS from Sigma (St. Louis, MO) for 5 min. Ten percent normal horse serum (Vector Laboratories, Burlingame, CA) in Tris-buffered saline (TBS, from Dako) was used as a blocking buffer to suppress background staining (60 min at 37°C). Endogenous peroxidase activity was inactivated with 3% H2O2 for 5 min. After each of the steps, slides were washed with TBS. Per the instructions in the Dako kit, the primary antibody was reacted with the biotinylated secondary antibody and blocking reagent before the antibodies were applied to the tissue sections. Primary antibody concentrations in the reaction mixtures were 5 µg/ml for anti-nNOS and anti-eNOS and 10 µg/ml for anti-iNOS. Reaction time for the antibodies on the sections was 15 min. Sections were treated with the streptavidin plus peroxidase reaction (15 min) and diaminobenzidine-chromagen staining (5 min). Sections were then rinsed in distilled water, lightly stained with Delafield's hematoxylin, and coverslipped.Statistical methods. All data are presented as means ± SD. Statistical significance was tested by paired t-test for within-group comparisons and were analyzed by the multiple analysis of variance followed by Scheffé's and Bonferroni/Dunn post hoc tests corrected for multiple comparisons of similar data sets and for comparisons over time. A commercial software package (Statistical Package for the Social Sciences for Windows; SPSS, Chicago, IL) was used. Statistical significance was defined as P < 0.05.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Group A: effects of selective and nonselective NOS inhibition on
exhaled NO excretion and PAP in normoxia and hypoxia.
There was no significant decrease in exhaled NO following
administration of 1400W and 7-NI compared with control or baseline levels of exhaled NO, but L-NAME (10 and 100 µM) caused a
significant decrease (Fig. 1). There was
no statistical change in exhaled NO in the control group at any point
in the experiment. Baseline normoxic PAP did not change significantly
following the administration of any inhibitor (Fig.
2). PAP rose slightly but insignificantly following hypoxic challenges in the control group (Fig.
3) and following 1400W or 7-NI. There was
no difference in hypoxic PAP response between control and 1400W or
7-NI. With the administration of 10 µM L-NAME, however,
there was a highly significant twofold elevation in PAP following a
hypoxic challenge (11 ± 11 mmHg vs. baseline, 1.5 ± 1.0 mmHg, P < 0.03). Several animals did not tolerate the hypoxic challenge following 100 µM L-NAME, developing
unstable pulmonary hypertension and edema. Hence, this challenge was
dropped, and these data are not reported.
|
|
|
Group B: effect of ACh and NOS inhibitors on exhaled NO production
and PAP in normoxia and hypoxia.
There was a small, statistically significant increase
(P < 0.05, one-sided paired t-test) in
exhaled NO with ACh infusion when the data from both the control and
the experimental groups were pooled. Baseline NO was 58 ± 16 before and 63 ± 15 ppb after acetylcholine. Figure
4 shows no significant change in expired NO with administration of 1400W or 7-NI in this preparation. Exhaled NO
fell markedly with administration of L-NAME at both
concentrations (P = 0.001) compared with baseline.
|
|
|
Group C: effect of nebulized L-NAME on exhaled
NO excretion and PAP in normoxia and hypoxia.
Figure 7 shows a steady progressive
decrease in exhaled NO with increasing doses of nebulized
L-NAME from 100 to 1,000 µM. Statistical significance
(P = 0.02) began at 750 µM, whereas exhaled NO in the
control group remained constant compared with baseline. Paralleling the
fall in exhaled NO, Fig. 8 shows a
progressive increase in the PAP change with hypoxia with significance
beginning at 500 µM (P = 0.02). The PAP increase with
hypoxia in the control group stayed relatively constant over the same
time interval. Even after the highest dose nebulization of
L-NAME, there was no detectable drug in the perfusate (<5
µM; the lower limit of detection of the amino acid analysis).
|
|
NOS immunohistochemistry of rabbit lung.
Figure 9 shows the results of NOS isozyme
immunohistochemistry in the lungs of normal healthy rabbits. By
immunohistochemistry, there is definite cellular staining (tan to
brown) for nNOS (NOS type I) and eNOS (NOS type III), with the
latter showing greater staining intensity and more extensive cellular
expression. Without primary antibody, no reaction product is found.
These sections only show the blue hematoxylin staining.
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
NOS isozyme contributions to exhaled NO. We have shown by using selective and nonselective NOS inhibitors that almost all exhaled NO in the isolated perfused rabbit lung is produced by eNOS and that only eNOS-derived NO modulates HPV. The extensive expression of eNOS by immunocytochemistry in the vascular endothelium as well as in the airway and alveolar epithelia, with very little nNOS and iNOS expression, further confirms this interpretation of the pharmacological data.
To our knowledge this work is the first to use isozyme-specific inhibitors to determine the isozyme origins of expired NO from the lower respiratory tract (airways distal to the larynx and lung parenchyma). DeSanctis et al. (8) measured differences in exhaled NO between tracheotomized normal mice and mice with a targeted deletion of nNOS and reported that nNOS is responsible for 40% of expired NO. The difference between our work and that of DeSanctis et al. (8) may represent either a species difference in lung NOS isozyme expression or an indirect effect of the gene deletion on other factors that control exhaled NO occurring in development that allows for survival to maturity without nNOS. Steudel et al. (32) studied total exhaled gas in awake, spontaneously breathing mice with targeted deletions of all three isozymes. Surprisingly, in this study, which necessarily included NO produced by the nasal passages, there was no reduction of NO production with the iNOS deficiency and, interestingly, increased amounts of NO produced by the nNOS- and eNOS-deficient mice. There is no easy explanation for these results, but they point again to the complexity and difficulty in analysis of nonconditional gene knockout models as alluded to above.NOS isozyme contributions to HPV. The absence of any difference in hypoxic PAP between control and intervention groups given 1400W and 7-NI strongly suggests that eNOS is the isozyme responsible for modulating HPV in the rabbit. Our NOS inhibitor results are in accord with the findings in NOS isozyme knockout mice, that eNOS is the principal isozyme whose NO production modulates both normoxic and hypoxic pulmonary tone (8, 11). Interestingly, although the absolute rise in PAP with hypoxia was greater with L-NAME without ACh pretreatment (group A), there was a larger increase in PAP in the ACh group (group B) in response to NOS inhibitors compared with respective control animals (Figs. 3 and 6). The hypoxic response of eNOS inhibition contrasted with the effect of L-NAME under normoxia. In the latter circumstance, although there was a large drop (>75%) in exhaled NO, there was no significant change in PAP, suggesting that normoxic baseline NO secretion is a minor factor in vasoregulation in the absence of hemoglobin.
One limitation of this study is that we employed a single concentration of 7-NI and 1400W. We chose the doses based on earlier studies that suggest activity of these NOS inhibitors at these concentrations (24, 35), although there were no previous studies used in studies of the lung. We cannot completely exclude some small effect of these isozymes, especially nNOS, if higher doses had been used. Similarly, we chose the dose of the ACh infusion based on earlier studies (6). There was a small increase in exhaled NO with ACh but no change in PAP. This contrasts with another study in whole rabbits that received intravenous nitroglycerin and had a dose-dependent rise in exhaled NO with a concomitant decrease in PAP (24). This rise in NO was unaffected by high-dose (30 mg/kg), intravenous L-NAME. A larger dose of ACh might have simultaneously increased exhaled NO and decreased PAP. Another possibility is that the pulmonary vasculature in this model may have been maximally dilated or nearly so at rest that the ACh would have little effect. These results then suggest that baseline NO levels under normoxia do not significantly affect pulmonary vasoregulation in the isolated, buffer-perfused rabbit lung. Our study results are limited by the experimental model of the isolated, perfused rabbit lung. Thus our animals were perfused with nonpulsatile flow and were ventilated with zero PEEP. Carlin et al. (5) have shown that changing levels of PEEP change exhaled NO. When PEEP was increased, exhaled NO also increased. Also, these authors demonstrate decreased exhaled NO when flow was changed from nonpulsatile to pulsatile (5). These conditions remained unchanged during the study, but different ventilation or flow characteristics may have altered our data. Although our data and that of others (11, 12) suggest that vascular endothelium is important in regulating HPV, there is also an important contribution of airway eNOS-derived NO to pulmonary vascular regulation. It was our hypothesis in delivering L-NAME directly to the airways by nebulization that this route of administration would allow us to dissociate airway/alveolar NO production from vascular production. We reasoned that it might be possible to observe a reduction in exhaled NO before any augmentation of HPV occurred, a process generally considered to be dependent on a reduction of NO generated by the vasculature. However, the data in Figs. 7 and 8 clearly show that no such dissociation between HPV and exhaled NO change can be demonstrated. This intimate association of vascular responsiveness with airway and alveolar epithelial NO production is further supported by the lack of measurable L-NAME (<5 µM) in the perfusate even at the highest nebulized doses, a concentration well below the KI for L-NAME against eNOS of ~100 µM (3, 26). Thus it is most likely that nebulized L-NAME increased HPV by inhibiting airway and alveolar epithelial NO production and reducing the amount of NO available to diffuse from the airways to the vasculature. In support of this view, we have shown that dogs that exhaled NO may be reduced by three-quarters before any systemic hypertensive effect of nebulized L-NAME is measurable (2). Sartori et al. (27) drew similar conclusions in their analysis of the use of nebulized NOS inhibitors in humans. The caveat to this conclusion is that a small but sufficient amount of L-NAME may have diffused from the airways to bind to vascular eNOS and that complete scavenging by enzyme binding eliminated any drug available to accumulate in the perfusate.Anatomic sources of expired NO. The anatomic sources of exhaled NO from the lower respiratory tract (airways, alveolar epithelium, and vessels) have been difficult to quantitate not only for technical reasons but also owing to considerable species differences in the expression of and localization of the various NOS isozymes in the lung (reviewed in Ref. 13). There have been no NOS immunocytochemical studies of rabbit lungs reported heretofore.
eNOS. We found an extensive expression of eNOS in the airway epithelium (including the cilia), alveolar epithelium, and vascular endothelium of the rabbit, similar to the rat (37), but different from other mammals in which eNOS is not as strikingly expressed in the airways and alveoli. These findings are most consistent with a majority of exhaled NO arising from eNOS-derived NO from the airways and alveolar epithelium (1, 2, 4, 25, 27, 28). The rich expression of eNOS observed in the airways and alveolar epithelium of the rabbit may explain why this species has one of the highest concentrations of exhaled NO among mammals (2, 6, 7, 27).
nNOS. We found that nNOS is expressed in the bronchial epithelium in larger airways, specifically in the ciliated cells, but not mucous cells. This is consistent with findings in human lungs (16). The smaller airways show less intense nNOS staining. nNOS is present in lymphocytes associated with the BALT of the airways. Although nNOS is reported to be expressed in airway nerves of humans (16) and developing and adult mice (18), no definite staining of nerves was evident in any sections of rabbit airways we studied. As reported in human lungs (19), we found weak but definite staining in the capillary endothelium. Despite the presence of nNOS in the lung by immunohistochemistry, we could show only a nonstatistically significant small reduction in exhaled NO with 7-NI (Fig. 1). The reasons for the lack of drug effect may reflect the overwhelming dominant quantitative expression of eNOS in the rabbit lung, which makes detection of a small contribution difficult against a large background of eNOS-mediated production of NO.
iNOS. We could not detect iNOS in the airways or parenchyma of rabbits, except on cilia of the large airways. In fact, cilia in the large airways appear to contain all three isozymes. These findings are consistent with a role of local NO generation in rabbit airway ciliary motility (33) with upregulation with endotoxin challenge in rat lungs (10). Immunocytochemical evidence for all three isozymes has been reported for rat lungs (10, 37, 38). Although in humans and many species following inflammatory challenges (10, 13, 36) iNOS is readily detectable at the airway and alveolar levels, our studies were performed in pathogen-free rabbit lungs, so this may explain the lack of appreciable generalized airway and alveolar iNOS staining. The lack of effect of 1400W on exhaled NO in the healthy rabbit lung parallels the absence of any quantitative contribution of the small amount of ciliary iNOS isozyme present in the airways.
The amount of NO produced by the vasculature that reaches exhaled gas is likely quite small but may be detectable under certain conditions. We found an increase in exhaled NO when ACh was administered in the perfusate. ACh is a known stimulant of vascular endothelial NO, and our result is similar to the ACh-mediated increase in exhaled NO observed in the isolated perfused pig lung (6). Although it is possible that ACh might have also increased epithelial NO production, studies in normal humans and asthmatics have shown no increase in exhaled NO with inhalation of methacholine, a related cholinergic agonist. (9, 30). We have also demonstrated a small vascular contribution to exhaled NO with large nonpharmacological increases in vascular pressure and flow in the saline-perfused rabbit lung (1). Given the relatively small increase in exhaled NO when vascular NO production is stimulated in blood-free perfused lungs, it seems reasonable to assume that in vivo very little NO produced by the vascular endothelium could escape the avid binding by red blood cell hemoglobin and reach airway and alveolar gas (7, 21). In conclusion, we have shown pharmacologically and histochemically that, in the isolated perfused rabbit lung, most exhaled NO is produced by eNOS located in airways and alveolar epithelium and that this isozyme is involved in the modulation of HPV. A much smaller fraction of exhaled NO may derive from eNOS in the vascular endothelium. In the normal healthy rabbit, there is a small expression of nNOS in the airways that contributes minimally, if at all, to exhaled NO, and no expression of iNOS. ![]() |
ACKNOWLEDGEMENTS |
---|
The authors thank Dr. Rhona Jack for careful measurements of L-NAME concentrations and Shane Roberts for assistance in performing Western blots.
![]() |
FOOTNOTES |
---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-45591 and HL-03796-01.
Address for reprint requests and other correspondence: E. R. Swenson, Veterans Affairs Puget Sound Health Care System, Pulmonary and Critical Care Medicine, 1660 S. Columbian Way, Seattle, WA 98108 (E-mail: eswenson{at}u.washington.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published January 17, 2003;10.1152/ajplung.00341.2002
Received 15 October 2002; accepted in final form 14 January 2003.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Berg, JT,
Kerr ME,
Deem S,
and
Swenson ER.
Hemoglobin and red cells alter the expired nitric oxide response to mechanical forces in isolated lungs and live rabbits.
Am J Physiol Heart Circ Physiol
279:
H2947-H2953,
2000
2.
Brogan, TV,
Hedges RG,
Hlastala MP,
Robertson HT,
McKinney S,
and
Swenson ER.
Pulmonary nitric oxide synthase inhibition and inspired carbon dioxide: effects on VA/Q matching and pulmonary blood flow distributions.
Eur Respir J
16:
288-295,
2000
3.
Buxton, ILO,
Cheek DJ,
Eckman D,
Westfall DP,
Sanders KM,
and
Keef KD.
NG-Nitro-L-arginine and other alkyl esters of arginine are muscarinic receptor antagonists.
Circ Res
72:
387-395,
1993[Abstract].
4.
Byrnes, CA,
Dinarevic S,
Busst C,
Bush A,
and
Shinbourne EA.
Is nitric oxide in exhaled air produced at airway of alveolar levels.
Eur Respir J
10:
1021-1025,
1997
5.
Carlin, RE,
Ferrario L,
Boyd JT,
Camporesi EM,
Mcgraw DJ,
and
Hakim TS.
Determinants of nitric oxide in exhaled gas in the isolated rabbit lung.
Am J Respir Crit Care Med
155:
922-927,
1997[Abstract].
6.
Cremona, G,
Higgenbottam T,
Takao M,
Hall L,
and
Bower EA.
Exhaled nitric oxide in isolated pig lungs.
J Appl Physiol
78:
59-63,
1995
7.
Deem, S,
Swenson ER,
Alberts M,
Hedges RG,
and
Bishop MJ.
Red blood cell augmentation of hypoxic pulmonary vasoconstriction: hematocrit dependence and the importance of nitric oxide.
Am J Respir Crit Care Med
157:
1181-1186,
1998
8.
DeSanctis, GT,
Mehta S,
Kobzik L,
Yandava C,
Jiao A,
Huang PL,
and
Drazen JM.
Contribution of type I NOS to expired gas and bronchial responsiveness in mice.
Am J Physiol Lung Cell Mol Physiol
273:
L883-L888,
1997
9.
Deykin, A,
Belostotsky O,
Hong C,
Massaro A,
Lilly CM,
and
Israel E.
Exhaled nitric oxide following leukotriene E4 and methacholine inhalation in patients with asthma.
Am J Respir Crit Care Med
162:
1685-1689,
2000
10.
Emert, M,
Ruppert C,
Gunther A,
Duncker HR,
Seeger W,
and
Emert L.
Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs.
Lab Invest
82:
425-441,
2002[ISI][Medline].
11.
Fagan, KA,
Fouty BW,
Tyler RC,
Morris KG,
Hepler LK,
Sato K,
LeCras TD,
Abman SH,
Weinberger HD,
Huang PL,
McMurtry IF,
and
Rodman DM.
The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia.
J Clin Invest
103:
291-299,
1999
12.
Fagan, KA,
Tyler RC,
Sato K,
Fouty BW,
Morris KG,
Huang PL,
McMurtry IF,
and
Rodman DM.
Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation.
Am J Physiol Lung Cell Mol Physiol
277:
L472-L478,
1999
13.
Fischer, A.
Localization of nitric oxide synthases in the lung.
In: Nitric Oxide in Pulmonary Processes in Physiology and Pathophysiology of Lung Disease, edited by Belvisi MG,
and Mitchell JA.. Basel: Birkhauser, 2000, p. 71-88.
14.
Furchgott, RF,
and
Zawadzki JV.
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature
288:
373-376,
1980[ISI][Medline].
15.
Gerlach, H,
Rossaint R,
Pappert D,
Knorr M,
and
Falke KJ.
Auto-inhalation of nitric oxide after endogenous synthesis in nasopharynx.
Lancet
343:
518-519,
1994[ISI][Medline].
16.
Giaid, A.
Nitric oxide and endothelin-1 in pulmonary hypertension.
Chest
114:
208S-212S,
1998
17.
Grimminger, F,
Spriestersbach R,
Weissmann N,
Walmrath D,
and
Seeger W.
Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs.
J Appl Physiol
78:
1509-1515,
1995
18.
Guembe, L,
and
Villaro AC.
Histochemical demonstration of neuronal nitric oxide synthase during development of the mouse respiratory tract.
Am J Respir Cell Mol Biol
20:
342-351,
1999
19.
Luhrs, H,
Papadopoulos T,
Schmidt HHW,
and
Menzel T.
Type I nitric oxide synthase in the human lung is predominantly expressed in capillary endothelial cells.
Respir Physiol
129:
367-374,
2002[ISI][Medline].
20.
Lundberg, JO,
Weitzberg E,
Nordvall SL,
Kuylenstierna R,
Lundberg JM,
and
Alving K.
Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome.
Eur Respir J
7:
1501-1504,
1994
21.
Mayer, BX,
Mensik C,
Krishnaswami S,
Derendorf H,
Eichler H-G,
Schmetterer L,
and
Wolzt M.
Parmacokinetics-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans.
Br J Clin Pharmacol
47:
539-544,
1999[ISI][Medline].
22.
Moore, PK,
Babbedge RC,
Wallace P,
Gaffen ZA,
and
Hart SL.
7-Nitroindazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure.
Br J Pharmacol
108:
296-297,
1993[Abstract].
23.
Parrino, PE,
Laubach VE,
Gaughen JRJ,
Shockey KS,
Wattsman TA,
King RC,
Tribble CG,
and
Kron IL.
Inhibition of inducible nitric oxide synthase after myocardial ischemia increases coronary flow.
Ann Thorac Surg
66:
733-739,
1998
24.
Persson, MG,
Agvald P,
and
Gustafsson LE.
Detection of nitric oxide in exhaled air during administration of nitroglycerin in vivo.
Br J Pharmacol
111:
825-828,
1994[Abstract].
25.
Pietropaoli, AP,
Perillo IB,
Torres A,
Perkins PT,
Frasier LM,
Utell MJ,
Frampton MW,
and
Hyde RW.
Simultaneous measurement of nitric oxide production by conducting and alveolar airways of humans.
J Appl Physiol
87:
1532-1542,
1999
26.
Rees, DD,
Palmer RM,
Schulz R,
Hodson HF,
and
Moncada S.
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.
Br J Pharmacol
101:
746-752,
1990[Abstract].
27.
Sartori, C,
Lepori M,
Busch T,
Duplain H,
Hildebrandt W,
Bartsch P,
Nicod P,
Falke KJ,
and
Scherrer U.
Exhaled nitric oxide does not provide a marker of vascular endothelial function in healthy humans.
Am J Respir Crit Care Med
160:
879-882,
1999
28.
Schedin, U,
Frostell C,
and
Gustafsson LE.
Nitric oxide occurs in high concentrations in monkey upper airways.
Acta Physiol Scand
155:
473-474,
1995[ISI][Medline].
29.
Schedin, U,
Frostell C,
Persson MG,
Jakobsson J,
Andersson G,
and
Gustafsson LE.
Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans.
Acta Anaesthesiol Scand
39:
327-332,
1995[ISI][Medline].
30.
Silvestri, M,
Spallarossa D,
Battistini E,
Brusasco V,
and
Rossi GA.
Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma.
Thorax
55:
484-488,
2000
31.
Slocum, RH,
and
Cummings JG.
Amino acid analysis of physiological samples.
In: Techniques in Diagnostics Human Biochemical Genetics: A Laboratory Manual, edited by Homer FA.. New York: Wiley-Liss, 1991, p. 87-126.
32.
Steudel, W,
Kirmse M,
Weimann J,
Ullrich R,
Hromi J,
and
Zapol WM.
Nitric oxide production by nitric oxide synthase-deficient mice.
Am J Respir Crit Care Med
162:
1262-1267,
2000
33.
Tamaoki, J,
Chiyotani A,
Kondo M,
and
Konno K.
Role of NO generation in -adrenoceptor-mediated stimulation of rabbit airway ciliary motility.
Am J Physiol Cell Physiol
268:
C1342-C1347,
1995
34.
Thomsen, LL,
Scott JM,
Topley P,
Knowles RG,
Keerie AJ,
and
Frend AJ.
Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor.
Cancer Res
57:
3300-3304,
1997[Abstract].
35.
Wang, H,
Carretero OA,
and
Garvin JL.
Nitric oxide produced by THAL nitric oxide synthase inhibits TGF.
Hypertension
39:
662-666,
2002
36.
Watkins, DN,
Peronie DJ,
Basclain KA,
Garlepp MJ,
and
Thompson PJ.
Expression and activity of nitric oxide synthases in human airway epithelium.
Am J Respir Cell Mol Biol
16:
629-639,
1997[Abstract].
37.
Xue, C,
Botkin SJ,
and
Johns RA.
Localization of endothelial NOS at the basal microtubule membrane in ciliated epithelium of rat lung.
J Histochem Cytochem
44:
463-471,
1996
38.
Zhan, X,
Li D,
and
Johns RA.
Immunocytochemical evidence for the NO cGMP signaling pathway in respiratory ciliated epithelia of rat.
J Histochem Cytochem
47:
1369-1374,
1999